Astra Zeneca
AstraZeneca PLC, a global biopharmaceutical company, is headquartered in Cambridge, United Kingdom, with significant operations across North America, Europe, and Asia. Founded in 1999 through the merger of Astra AB and Zeneca Group, the company has since established itself as a leader in the pharmaceutical industry, focusing on innovative medicines in areas such as oncology, cardiovascular, renal, and respiratory diseases. AstraZeneca's core products include a range of prescription medications that are distinguished by their commitment to research and development, particularly in biologics and precision medicine. The company has achieved notable milestones, including the rapid development of its COVID-19 vaccine, which underscored its position as a key player in global health. With a strong market presence and a dedication to advancing healthcare, AstraZeneca continues to make significant contributions to medical science and patient care.
DitchCarbon Score
How does Astra Zeneca's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Astra Zeneca's score of 46 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Astra Zeneca's reported carbon emissions
In 2023, AstraZeneca reported total greenhouse gas emissions of approximately 7.1 million tonnes CO2e, with emissions distributed across various scopes: about 180,898 tonnes CO2e from Scope 1, 19,940 tonnes CO2e from Scope 2, and around 6.7 million tonnes CO2e from Scope 3. The company has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its value chain by FY2045. AstraZeneca's near-term targets include a significant reduction of 98% in absolute Scope 1 and 2 emissions by FY2026, using FY2015 as a baseline. For Scope 3 emissions, the company aims to achieve a 50% reduction by FY2030 from a FY2019 baseline. Specific targets within this commitment include an 80% reduction in emissions from fuel and energy-related activities, upstream leased assets, and downstream leased assets by FY2030, as well as a 95% reduction in emissions from the use of sold products. Additionally, AstraZeneca has committed that by FY2025, 95% of its suppliers by spend on purchased goods and services and capital goods will have science-based targets, alongside 50% of suppliers covering upstream transportation and distribution and business travel. These initiatives reflect AstraZeneca's commitment to sustainability and its proactive approach to addressing climate change within the biopharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2015 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 298,498,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 322,319,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000,000 | 0,000,000,000 | 00,000,000,000 | 00,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Astra Zeneca is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
